Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A | NEJM - nejm.org

[news]

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A | NEJM (https://news.google.com/rss/articles/CBMiM2h0dHBzOi8vd3d3Lm5lam0ub3JnL2RvaS9mdWxsLzEwLj EwNTYvTkVKTW9hMjIxMTA3NdIBAA?oc=5) nejm.org
Hemophilia A Gene Therapy Durable at 2 Years; Under FDA Review (https://news.google.com/rss/articles/CBMiK2h0dHBzOi8vd3d3Lm1lZHNjYXBlLmNvbS92aWV3YXJ0aW NsZS85ODg1ODXSAQA?oc=5) Medscape
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B | NEJM (https://news.google.com/rss/articles/CBMiM2h0dHBzOi8vd3d3Lm5lam0ub3JnL2RvaS9mdWxsLzEwLj EwNTYvTkVKTW9hMjIxMTY0NNIBAA?oc=5) nejm.org
Hemophilia A Gene Therapy — Some Answers, More Questions | NEJM (https://news.google.com/rss/articles/CBMiMmh0dHBzOi8vd3d3Lm5lam0ub3JnL2RvaS9mdWxsLzEwLj EwNTYvTkVKTWUyMjEyMzQ30gEA?oc=5) nejm.org
Gene Therapy for Hemophilia A | NEJM (https://news.google.com/rss/articles/CBMiMmh0dHBzOi8vd3d3Lm5lam0ub3JnL2RvLzEwLjEwNTYvTk VKTWRvMDA2OTE4L2Z1bGwv0gEA?oc=5) nejm.org
View Full Coverage on Google News (https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZjbmt0TXpZd1NoRUtEd2pMdk xIUkJoRmdZaU5XdE5OckJ5Z0FQAQ?hl=en-US&gl=US&ceid=US:en&oc=5)

More... (https://news.google.com/rss/articles/CBMiM2h0dHBzOi8vd3d3Lm5lam0ub3JnL2RvaS9mdWxsLzEwLj EwNTYvTkVKTW9hMjIxMTA3NdIBAA?oc=5)